Antimalarial Drug Sensitivity Profile of Western Kenya Plasmodium Falciparum Field Isolates Determined by a SYBR Green I in Vitro Assay and Molecular Analysis

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2011 Jul 8

PMID 21734121

Citations 26

Authors

Hoseah M Akala

Fredrick L Eyase

Agnes C Cheruiyot

Angela A Omondi

Bernhards R Ogutu

Norman C Waters

Jacob D Johnson

Mark E Polhemus

David C Schnabel

Douglas S Walsh

Affiliations

Soon will be listed here.

Abstract

In vitro drug sensitivity and molecular analyses of Plasmodium falciparum track drug resistance. DNA-binding fluorescent dyes like SYBR Green I may allow field laboratories, proximal to P. falciparum collection sites, to conduct drug assays. In 2007-2008, we assayed 121 P. falciparum field isolates from western Kenya for 50% inhibitory concentrations (IC(50)) against 6 antimalarial drugs using a SYBR Green I in vitro assay: 91 immediate ex vivo (IEV) and 30 culture-adapted, along with P. falciparum reference clones D6 (chloroquine [CQ] sensitive) and W2 (CQ resistant). We also assessed P. falciparum mdr1 (Pfmdr1) copy number and single nucleotide polymorphisms (SNPs) at four codons. The IC(50)s for IEV and culture-adapted P. falciparum isolates were similar, and approximated historical IC(50)s. For Pfmdr1, mean copy number was 1, with SNPs common at codons 86 and 184. The SYBR Green I assay adapted well to our field-based laboratory, for both IEV and culture-adapted P. falciparum, warranting continued use.

Citing Articles

Increased sensitivity of malaria parasites to common antimalaria drugs after the introduction of artemether-lumefantrine: Implication of policy change and implementation of more effective drugs in fight against malaria.

Okore W, Ouma C, Okoth R, Yeda R, Ingasia L, Mwakio E PLoS One. 2024; 19(6):e0298585.

PMID: 38900782 PMC: 11189199. DOI: 10.1371/journal.pone.0298585.

and antiplasmodial activities of approved drugs predicted to have antimalarial activities using chemogenomics and drug repositioning approach.

Ochora D, Mogire R, Masai R, Yeda R, Mwakio E, Amwoma J Heliyon. 2023; 9(8):e18863.

PMID: 37583763 PMC: 10424068. DOI: 10.1016/j.heliyon.2023.e18863.

Isoliensinine from Cissampelos pariera rhizomes exhibits potential gametocytocidal and anti-malarial activities against Plasmodium falciparum clinical isolates.

Muema J, Mutunga J, Obonyo M, Getahun M, Mwakubambanya R, Akala H Malar J. 2023; 22(1):161.

PMID: 37208735 PMC: 10199507. DOI: 10.1186/s12936-023-04590-7.

Antiplasmodial, Cytotoxicity, and Antioxidant Activities of (Ochnaceae): A Cameroonian Plant Commonly Used to Treat Malaria.

Azizi M, Christelle Nadia N, Cedric Y, Guy-Armand G, Aboubakar Sidiki N, Jemimah Sandra T J Trop Med. 2023; 2023:4061592.

PMID: 36820149 PMC: 9938790. DOI: 10.1155/2023/4061592.

Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs.

Wakoli D, Ondigo B, Ochora D, Amwoma J, Okore W, Mwakio E BMC Med. 2022; 20(1):448.

PMID: 36397090 PMC: 9673313. DOI: 10.1186/s12916-022-02652-2.

References

Wein S, Maynadier M, Van Ba C, Cerdan R, Peyrottes S, Fraisse L . Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol. 2010; 48(5):1651-60. PMC: 2863886. DOI: 10.1128/JCM.02250-09. View

Holmgren G, Bjorkman A, Gil J . Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya. Trop Med Int Health. 2006; 11(12):1808-12. DOI: 10.1111/j.1365-3156.2006.01742.x. View

Shretta R, Omumbo J, Rapuoda B, Snow R . Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000; 5(11):755-64. DOI: 10.1046/j.1365-3156.2000.00643.x. View

Purfield A, Nelson A, Laoboonchai A, Congpuong K, McDaniel P, Miller R . A new method for detection of pfmdr1 mutations in Plasmodium falciparum DNA using real-time PCR. Malar J. 2004; 3:9. PMC: 420476. DOI: 10.1186/1475-2875-3-9. View

de Monbrison F, Raynaud D, Latour-Fondanaiche C, Staal A, Favre S, Kaiser K . Real-time PCR for chloroquine sensitivity assay and for pfmdr1-pfcrt single nucleotide polymorphisms in Plasmodium falciparum. J Microbiol Methods. 2003; 54(3):391-401. DOI: 10.1016/s0167-7012(03)00086-1. View

Siringi S . Over-the-counter sale of antimalaria drugs stalls Kenyan disease strategy. Lancet. 2001; 357(9271):1862. DOI: 10.1016/S0140-6736(00)05025-X. View

Ferreira I, do Rosario V, Cravo P . Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in Plasmodium falciparum. Malar J. 2006; 5:1. PMC: 1363351. DOI: 10.1186/1475-2875-5-1. View

Rason M, Randriantsoa T, Andrianantenaina H, Ratsimbasoa A, Menard D . Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg. 2008; 102(4):346-51. DOI: 10.1016/j.trstmh.2008.01.021. View

Zhong D, Afrane Y, Githeko A, Cui L, Menge D, Yan G . Molecular epidemiology of drug-resistant malaria in western Kenya highlands. BMC Infect Dis. 2008; 8:105. PMC: 2533336. DOI: 10.1186/1471-2334-8-105. View

10.

Nelson A, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sriwichai S . pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am J Trop Med Hyg. 2005; 72(5):586-92. View

11.

Uhlemann A, Krishna S . Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr Top Microbiol Immunol. 2005; 295:39-53. DOI: 10.1007/3-540-29088-5_2. View

12.

Mbaisi A, Liyala P, Eyase F, Achilla R, Akala H, Wangui J . Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya. Antimicrob Agents Chemother. 2004; 48(9):3598-601. PMC: 514731. DOI: 10.1128/AAC.48.9.3598-3601.2004. View

13.

Desjardins R, Canfield C, Haynes J, Chulay J . Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979; 16(6):710-8. PMC: 352941. DOI: 10.1128/AAC.16.6.710. View

14.

Bacon D, Latour C, Lucas C, Colina O, Ringwald P, Picot S . Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother. 2007; 51(4):1172-8. PMC: 1855478. DOI: 10.1128/AAC.01313-06. View

15.

Duraisingh M, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst D . The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000; 108(1):13-23. DOI: 10.1016/s0166-6851(00)00201-2. View

16.

Plowe C, Cortese J, Djimde A, Nwanyanwu O, WATKINS W, Winstanley P . Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997; 176(6):1590-6. DOI: 10.1086/514159. View

17.

Jafari S, Le Bras J, Bouchaud O, Durand R . Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis. 2004; 189(2):195-203. DOI: 10.1086/380910. View

18.

Malakooti M, Biomndo K, Shanks G . Reemergence of epidemic malaria in the highlands of western Kenya. Emerg Infect Dis. 1998; 4(4):671-6. PMC: 2640260. DOI: 10.3201/eid0404.980422. View

19.

Khan B, Omar S, Kanyara J, Warren-Perry M, Nyalwidhe J, Peterson D . Antifolate drug resistance and point mutations in Plasmodium falciparum in Kenya. Trans R Soc Trop Med Hyg. 1997; 91(4):456-60. DOI: 10.1016/s0035-9203(97)90284-4. View

20.

Mookherjee S, Howard V, Watkins W, Sibley C . Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples. Am J Trop Med Hyg. 1999; 61(1):131-40. DOI: 10.4269/ajtmh.1999.61.131. View